Rilpivirine inhibits SARS-CoV-2 protein targets: A potential multi-target drug

BACKGROUND: COVID-19 disease caused by SARS-CoV-2 is lacking efficient medication although certain medications are used to relief its symptoms. OBJECTIVES: We tested an FDA-approved antiviral medication namely rilpivirine to find a drug against SARS-CoV-2. METHODS: The inhibition of rilpivirine agai...

Descripción completa

Detalles Bibliográficos
Autores principales: Ameen, Fuad, Mamidala, Estari, Davella, Rakesh, Vallala, Shravan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Authors. Published by Elsevier Ltd on behalf of King Saud Bin Abdulaziz University for Health Sciences. 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8294774/
https://www.ncbi.nlm.nih.gov/pubmed/34326009
http://dx.doi.org/10.1016/j.jiph.2021.07.012

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8294774/
https://www.ncbi.nlm.nih.gov/pubmed/34326009
http://dx.doi.org/10.1016/j.jiph.2021.07.012

Ejemplares similares